MAPK6 and prostate carcinoma: Accordingly, knockdown of MAPK6 in four cancer cell lines with medium to high expression of endogenous MAPK6 (MCF7 and SUM159 for breast cancer, PC3 for prostate cancer, and H1299 for non–small cell lung cancer) inhibited cell growth in vitro and/or xenograft growth in vivo.